<--- Back to Details
First PageDocument Content
Metastasis / Oncology
Date: 2012-03-05 17:39:49
Metastasis
Oncology

Statement of Work Title: HuR, an mRNA-binding protein as molecular target for lung cancer therapy Aim 1: Evaluate HuRsiRNA-nanoparticle (NP)-mediated inhibitory effect on lung tumor growth and metastasis in a tumor xeno

Add to Reading List

Source URL: www.ouhsc.edu

Download Document from Source Website

File Size: 11,29 KB

Share Document on Facebook

Similar Documents

#4503 A Small Molecule Glycomimetic Antagonist of E-selectin (GMIPrevents Pancreatic Tumor Metastasis and Offers Improved Efficacy of Chemotherapy Maria M. Steele1, BS, Prakash Radhakrishnan1, PhD, John L. Magnani

#4503 A Small Molecule Glycomimetic Antagonist of E-selectin (GMIPrevents Pancreatic Tumor Metastasis and Offers Improved Efficacy of Chemotherapy Maria M. Steele1, BS, Prakash Radhakrishnan1, PhD, John L. Magnani

DocID: 1vkKU - View Document

Quantitative image-based phenotypes for cancer metastasis systems biology Joel S. Bader, Ph.D. Professor, Biomedical Engineering Johns Hopkins University

Quantitative image-based phenotypes for cancer metastasis systems biology Joel S. Bader, Ph.D. Professor, Biomedical Engineering Johns Hopkins University

DocID: 1vd8y - View Document

A	
  small	
  molecule	
  glycomime.c	
  antagonist	
   of	
  E-­‐selec.n	
  and	
  CXCR4	
  (GMI-­‐1359)	
   delays	
  pancrea.c	
  tumor	
  metastasis	
  and	
   significantly	
  alters	
  the

A  small  molecule  glycomime.c  antagonist   of  E-­‐selec.n  and  CXCR4  (GMI-­‐1359)   delays  pancrea.c  tumor  metastasis  and   significantly  alters  the

DocID: 1uubq - View Document

Why we focus on Metastasis & Invasion Around 90% of cancer deaths are attributable to invasion and metastasis. Metastasis is the spread of disease from one organ or part to another not directly connected with the primary

Why we focus on Metastasis & Invasion Around 90% of cancer deaths are attributable to invasion and metastasis. Metastasis is the spread of disease from one organ or part to another not directly connected with the primary

DocID: 1sjoH - View Document

Nota de Prensa LA FDA APRUEBA DENOSUMAB PARA LA PREVENCIÓN DE EVENTOS ESQUELÉTICOS EN PACIENTES CON METÁSTASIS ÓSEAS DE TUMORES SÓLIDOS BARCELONA. (nov. 19, 2010) – La FDA ha aprobado denosumab, el primer y

Nota de Prensa LA FDA APRUEBA DENOSUMAB PARA LA PREVENCIÓN DE EVENTOS ESQUELÉTICOS EN PACIENTES CON METÁSTASIS ÓSEAS DE TUMORES SÓLIDOS BARCELONA. (nov. 19, 2010) – La FDA ha aprobado denosumab, el primer y

DocID: 1s5nh - View Document